Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

309.20 -4.02 (-1.28%)
Streaming Delayed Price Updated: 12:32 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
1 Growth Stock to Stash and 2 Facing Challenges
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Prime Value Investment with Strong Fundamentals and Undervalued Potential
UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech... 
Via Chartmill
UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per... 
Via StockStory
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Preview: United Therapeutics's Earnings
 
Via Benzinga
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It
The company is working through a patent battle that could seriously hamper sales of its new drug. 
Via Investor's Business Daily
Topics Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen
United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors. 
Via Chartmill
Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy
UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech... 
Via Chartmill
Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility
Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft... 
Via MarketMinute
Topics Economy Emissions
Forecasting The Future: 8 Analyst Projections For United Therapeutics
 
Via Benzinga
Earnings Summary on United Therapeutics
Via The Motley Fool
Topics Intellectual Property
United Therapeutics Stock Slides On Q2 Earnings: The Details
United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report. 
Via Benzinga
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share... 
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential
UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech. 
Via Chartmill
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers. 
Via StockStory
Topics Artificial Intelligence
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors. 
Via Chartmill
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors. 
Via Chartmill
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.